Understanding arbovirus infections in New Caledonia
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
NA · Institut Pasteur · NCT04619823
This study is trying to understand how viruses like Zika, Dengue, and Chikungunya affect people in New Caledonia by looking at blood samples from adults who show signs of these infections.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Pasteur (industry) |
| Locations | 1 site (Dumbéa Sur Mer) |
| Trial ID | NCT04619823 on ClinicalTrials.gov |
What this trial studies
This study investigates the virological and immunological factors that contribute to arbovirus infections, such as Zika, Dengue, and Chikungunya, particularly in New Caledonia. It involves collecting blood samples from adult patients exhibiting clinical signs of these infections to enhance the understanding of how these viruses replicate and how the immune system responds. The research aims to improve the reliability of vector competence experiments and provide insights into the mechanisms of infection. The study presents minimal risks and constraints for participants.
Who should consider this trial
Good fit: Ideal candidates are adults showing clinical signs of arbovirus infection, such as fever and additional symptoms, within the last week.
Not a fit: Patients with other identified viral infections, inflammatory diseases, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to better prevention and treatment strategies for arbovirus infections.
How similar studies have performed: Other studies have shown success in understanding arbovirus infections through similar methodologies, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patient * Patient with clinical signs suggestive of an arbovirus infection: Fever And at least 2 clinical signs suggestive of arbovirus among which myalgia, retro-orbital pain, drop in platelets (if data available), digestive symptoms, etc. * Appearance of clinical signs suggestive of an arbovirus infection in the 7 days preceding the blood sample. * Patient informed of the performance of the research, the collection of data and biological samples * Patient who has given their consent to participate in the research by authorizing the collection of data, the collection of an additional blood sample and the use of this sample Exclusion Criteria: * Patient suffering from another identified virosis, an inflammatory disease or taking anti-inflammatory drugs * Pregnant patient * Patient returning from a trip within 15 days before the onset of the signs, * Patient for whom the blood sample is incomplete or could not be performed * Patient's condition, which, in the doctor's opinion, is incompatible with the additional sample required by the study * Patient not having consented to participate in the research
Where this trial is running
Dumbéa Sur Mer
- Centre Hospitalier Territorial de Nouvelle-Calédonie — Dumbéa Sur Mer, New Caledonia (RECRUITING)
Study contacts
- Principal investigator: Myrielle Dupont-Rouzeyrol, PhD — Institut Pasteur de Nouvelle-Calédonie
- Study coordinator: Myrielle Dupont-Rouzeyrol, PhD
- Email: mdupont@pasteur.nc
- Phone: +687 27 75 30
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Arbovirus Infections, Zika, Dengue, Chikungunya, New Caledonia